Hospital Performance With Myocardial Reperfusion Therapy: Are Hospitals Capable of Meeting Established Guidelines?

Critical Pathways in Cardiology

Volumn 2, Issue 3, 2003, Pages 197-206

  Sutter, Robert ^a  

^a Texas Tech University Health Sciences Center   (United States)

Author keywords

AMI reperfusion; CPU; Process capability; Quality measurement

Indexed keywords

ARTICLE; BLOOD CLOT LYSIS; CORONARY ARTERY DILATATION; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEART MUSCLE REPERFUSION; HUMAN; MEASUREMENT; PERFORMANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELIABILITY; UNITED STATES;

EID: 0142259194     PISSN: 1535282X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HPC.0000085365.55020.7f     Document Type: Article

References (37)

1. Cannon CP, Gibson CM, Lambrew CT, et al. Longer thrombolysis door-to-needle times are associated with increased mortality in acute myocardial infarction: an analysis of 85,589 patients in the National Registry of Myocardial Infarction 2 + 3. J Am Coll Cardiol. 2000;35(2, Suppl. A):864-1.
2. Berger PB, Ellis SG, Holmes DR, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction. Circulation. 1999;100:14-20.
3. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283:2941-2947.
4. Chareonthaitawee P, Gibbons RJ, Roberts RS, et al. The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. Heart. 2000;84:142-148.
5. Cannon CP, Braunwald E. Time to reperfusion: the critical modulator in thrombolysis and primary angioplasty. J Thromb Thrombolysis. 1996;3:117-125.
6. Appleby P, Baigent C, Collins R, et al. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994;343:311-322.
7. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
8. Simes RJ, Topol EJ, Holmes DR, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Circulation. 1995;91:1923-1928.
9. Kleiman NS, White HD, Ohman M, et al. Mortality within 24 hours of thrombolysis for myocardial infarction. Circulation. 1994;90:2658-2665.
10. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
11. Vogt A, von Essen R, Tebbe U, et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol. 1993;21:1391-1395.
12. Lundergan CF, Ross AM, McCarthy WF, et al. Predictors of left ventricular function after acute myocardial infarction: effects of time to treatment, patency, and body mass index. Am Heart J. 2001;142:43-50.
13. Brodie BR, Stuckey TD, Wall TC, et al. Importance of reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1998;32:1312-1319.
14. Committee on Management of Acute Myocardial Infarction. ACC/AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol. 1996;5:1328-1428.
15. Committee on Management of Acute Myocardial Infarction. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol. 1999;3:890-911.
16. Joint Commission on Accreditation of Healthcare Organizations. Information on final specifications for national implementation of hospital core measures. Available at: http://www.jcaho.ocg/perfmeas/coremeas/Core_Manual.htm. Accessed March 8, 2002.
17. Kotz S, Lovelace CR. Process Capability Indices in Theory and Practice. New York: Arnold; 1998.
18. Montgomery DC. Introduction to Statistical Quality Control. 3rd ed. New York: John Wiley & Sons; 1997.
19. Wheeler DJ. Beyond Capability Confusion: The Average Cost-of-Use. Knoxville, TN: SPC Press; 1999.
20. Wheeler DJ. Understanding Statistical Process Control. Knoxville, TN: SPC Press; 1992.
21. Leitnaker MG, Sanders RD, Hild C. The Power of Statistical Thinking Improving Industrial Processes. Reading, PA: Addison-Wesley Publishing Co; 1996.
22. SAS Institute. SAS/QC User's Guide, Version 8. Cary, NC: SAS Institute; 1999.
23. Lambrew CT, Bowlby LJ, Rogers WJ, et al. Factors influencing the time to thrombolysis in acute myocardial infarction. Arch Int Med. 1997;157:2577-2582.
24. Sharkey SW, Brunette DD, Ruiz E, et al. An analysis of time delays preceding thrombolysis for acute myocardial infarction. JAMA. 1989;262:3171-3174.
25. Cannon CP, Antman EM, Walls R, et al. Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombolysis. 1994;1:27-34.
26. Maynard C, Weaver WD, Lambrew C, et al. Factors influencing the time to administration of thrombolytic therapy with recombinant tissue plasminogen activator. Am J Cardiol. 1995;76:548-552.
27. Palmer DJ, Cox KL, Dear K, et al. Factors associated with delay in giving thrombolytic therapy after arrival at hospital. Med J Aust. 1998;168:111-114.
28. Hilleman DE, Gannon JM. Reducing time delays in the administration of thrombolytic therapy to patients with acute myocardial infarction. Ann Pharmacother. 1991;25:1096-1100.
29. Gonzalez ER, Jones LA, Ornato JP, et al. Hospital delays and problems with thrombolytic administration in patients receiving thrombolytic therapy: a multicenter prospective assessment. Ann Emerg Med. 1992;21:1215-1221.
30. Hirvonen TPJ, Hallinen MO, Kala RA, et al. Delays in thrombolytic therapy for acute myocardial infarction in Finland. Eur Heart J. 1998;19:885-892.
31. Lambrew CT, Weaver WD, Rogers WJ, et al. Hospital protocols and policies that may delay early identification and thrombolytic therapy of acute myocardial infarction patients. J Thromb Thrombolysis. 1996;3:301-306.
32. National Heart Attack Alert Program Coordinating Committee. Emergency department: rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med 1994;23:311-329.
33. Wallentin L. Reducing time to treatment in acute myocardial infarction. Eur J Emerg Med. 2000;7:217-227.
34. Every NR, Frederick PD, Robinson M, et al. A comparison of the National Registry of Myocardial Infarction 2 with the Cooperative Cardiovascular Project. J Am Coll Cardiol. 1999;33:1886-1894.
35. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with Acute myocardial infarction: a four-state pilot study from the Cooperative Cardiovascular Project. JAMA. 1995;273:1509-1514.
36. Schuster MA, McGlynn EA, Brook RH. "How good is the quality of health care in the United States? Milbank Q 1998;76:517-563.
37. Kizer KW. Establishing health care performance standards in an era of consumerism. JAMA. 2001;286:1213-1217.